Page last updated: 2024-12-07
4-iodo-n-piperidinoethylbenzamide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4-iodo-N-piperidinoethylbenzamide: a malignant melanoma imaging agent; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 127898 |
| CHEMBL ID | 1601095 |
| CHEBI ID | 93391 |
| SCHEMBL ID | 1512655 |
| MeSH ID | M0224895 |
Synonyms (38)
| Synonym |
|---|
| 4-iodo-n-(2-(1-piperidinyl)ethyl)benzamide |
| 4-iodo-n-[2-(1-piperidyl)ethyl]benzamide |
| HMS3266B14 |
| BRD-K78844995-001-01-8 |
| NCI60_022565 |
| nsc665366 |
| nsc-665366 |
| tocris-0763 |
| NCGC00024776-01 |
| NCGC00024776-02 |
| 4-iodo-n-(2-piperidin-1-ylethyl)benzamide |
| AKOS009472810 |
| n-(2-(piperidinylamino)ethyl)-4-iodobenzamide |
| 4-ipab |
| 4-iodo-n-piperidinoethylbenzamide |
| 155054-42-5 |
| benzamide, 4-iodo-n-(2-(1-piperidinyl)ethyl)- |
| (125)i-pab |
| (i125)-(2-piperidinylaminoethyl)-4-iodobenzamide |
| ipab |
| n-[2-(piperidinylamino)ethyl]-4-iodobenzamide |
| CHEMBL1601095 |
| SCHEMBL1512655 |
| SR-01000597707-1 |
| sr-01000597707 |
| CHEBI:93391 |
| Z422647636 |
| 4-iodo-n-[2-(piperidin-1-yl)ethyl]benzamide |
| 4-iodo-n-[2-(1-piperidinyl)ethyl]benzamide |
| Q27165093 |
| HMS3675H17 |
| DTXSID60935122 |
| HMS3411H17 |
| F82108 |
| benzamide, 4-iodo-n-[2-(1-piperidinyl)ethyl]- |
| CS-0020977 |
| PD021939 |
| EN300-1695990 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| carbonyl compound | Any compound containing the carbonyl group, C=O. The term is commonly used in the restricted sense of aldehydes and ketones, although it actually includes carboxylic acids and derivatives. |
| organohalogen compound | A compound containing at least one carbon-halogen bond (where X is a halogen atom). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (5)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 16.3601 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 10.0000 | 0.0020 | 7.5337 | 39.8107 | AID891 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 31.6228 | 0.0063 | 6.9043 | 39.8107 | AID883 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 25.1189 | 0.3162 | 12.7657 | 31.6228 | AID881 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 29.0212 | 0.0063 | 8.2350 | 39.8107 | AID881; AID883 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (21)
Molecular Functions (8)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| iron ion binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| calcium ion binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| protein binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| lipid binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| linoleate 13S-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| arachidonate 8(S)-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| arachidonate 15-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| linoleate 9S-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (8)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleus | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| cytosol | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| cytoskeleton | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| plasma membrane | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| adherens junction | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| focal adhesion | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| membrane | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| extracellular exosome | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.72
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||